Vivo Capital’s Ovid Therapeutics OVID Stock Holding History

Vivo Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,250,000	Closed	-$2.89M	–	65
2020 Q4	$2.89M	Hold	1,250,000	–	–	0.13%	53
2020 Q3	$7.17M	Buy	+1,250,000	New	+$8.36M	0.41%	47

Other funds holding OVID

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital's OVID Position: Q1 2021 in Review

Vivo Capital sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 1,250,000 shares — an estimated $2.89M sold.

Vivo Capital first reported a position in OVID in Q3 2020 and held it in 2 quarters. The position peaked at $7.17M in Q3 2020. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

Vivo Capital reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
Vivo Capital sold 1,250,000 Ovid Therapeutics shares in Q1 2021, an estimated $2.89M.
Vivo Capital first reported a position in Ovid Therapeutics in Q3 2020 and held it in 2 quarters.
Vivo Capital's Ovid Therapeutics position peaked at $7.17M in Q3 2020.
88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.